TY - JOUR
T1 - Head-to-head comparison of tau PET tracers [18F]PI-2620 and [18F]RO948 in non-demented individuals with brain amyloid deposition
T2 - the TAU-PET FACEHBI cohort
AU - on behalf of the FACEHBI study group
AU - on behalf of the AMYPAD consortium
AU - Tonietto, Matteo
AU - Sotolongo-Grau, Oscar
AU - Roé-Vellvé, Núria
AU - Bullich, Santiago
AU - Tartari, Juan Pablo
AU - Sanabria, Ángela
AU - García-Sánchez, Ainhoa
AU - Borroni, Edilio
AU - Galli, Christopher
AU - Pérez-Martínez, Esther
AU - Castell-Conesa, Joan
AU - Roca, Isabel
AU - Tárraga, Lluís
AU - Ruiz, Agustín
AU - Stephens, Andrew W.
AU - Boada, Mercè
AU - Klein, Gregory
AU - Marquié, Marta
AU - Vivas, A.
AU - Vargas, L.
AU - Valero, S.
AU - Torres, M.
AU - Terencio, J.
AU - Tejero, M. A.
AU - Seguer, S.
AU - Sarasa, M.
AU - Rosende-Roca, M.
AU - Ramis, M. I.
AU - Romero, J.
AU - Ricciardi, M.
AU - Pytel, V.
AU - Puerta, R.
AU - Preckler, S.
AU - Perissinotti, A.
AU - Pascual-Lucas, M.
AU - Pérez-Grijalba, V.
AU - Pérez-Cordon, A.
AU - Pelejà, E.
AU - Pancho, A.
AU - Páez, A.
AU - Ortega, G.
AU - Orellana, A.
AU - Olivé, C.
AU - Núñez, L.
AU - Nogales, A. B.
AU - Niñerola, A.
AU - Muñoz, N.
AU - Montrreal, L.
AU - Morera, A.
AU - Moreno, M.
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Background: Second-generation tau tracers for positron emission tomography (PET) show high affinity for paired helical filaments tau deposits characteristic of Alzheimer´s disease and low off-target binding. Differences in their chemical structure though may lead to variations in their regional tau uptake and off-target signal. In this work, we aimed to compare the in-vivo uptake of tau tracers [18F]PI-2620 and [18F]RO948 in the early stages of the AD continuum. Methods: Data from the TAU-PET FACEHBI clinical trial (EUDRA-CT 2021–000473-83) were analyzed. All participants were non-demented and underwent tau imaging with [18F]PI-2620 and [18F]RO948 PET within 3 months, amyloid imaging with [18F]Florbetaben and brain magnetic resonance imaging. Tau PET standardized uptake values ratios (SUVR) were calculated in Braak and typical off-target regions using the inferior cerebellar cortex as a reference region. Results: The cohort consisted of 18 individuals with subjective cognitive decline (n = 13) and mild cognitive impairment (n = 5), with centiloid values ranging from 17 to 159. Both tau tracers showed similar tau pathology distribution but presented a distinct off-target signal pattern on visual read. SUVR measurements for [18F]PI-2620 and [18F]RO948 were highly correlated in all Braak regions (R2 range [0.65–0.80]). Regarding off-target signal, [18F]PI-2620 had higher SUVRs in vascular structures, and [18F]RO948 had higher SUVRs in the skull/meninges. Conclusions: In a cohort of individuals at early stages of the AD continuum, tau PET tracers [18F]PI-2620 and [18F]RO948 showed similar in-vivo uptake in all Braak regions and distinct off-target signal. These preliminary results support the development of standardized quantification scales for tau deposition that are tracer-independent. Trial registration: AEMPS EudraCT 2021–000473-83. Registered 30 December 2021.
AB - Background: Second-generation tau tracers for positron emission tomography (PET) show high affinity for paired helical filaments tau deposits characteristic of Alzheimer´s disease and low off-target binding. Differences in their chemical structure though may lead to variations in their regional tau uptake and off-target signal. In this work, we aimed to compare the in-vivo uptake of tau tracers [18F]PI-2620 and [18F]RO948 in the early stages of the AD continuum. Methods: Data from the TAU-PET FACEHBI clinical trial (EUDRA-CT 2021–000473-83) were analyzed. All participants were non-demented and underwent tau imaging with [18F]PI-2620 and [18F]RO948 PET within 3 months, amyloid imaging with [18F]Florbetaben and brain magnetic resonance imaging. Tau PET standardized uptake values ratios (SUVR) were calculated in Braak and typical off-target regions using the inferior cerebellar cortex as a reference region. Results: The cohort consisted of 18 individuals with subjective cognitive decline (n = 13) and mild cognitive impairment (n = 5), with centiloid values ranging from 17 to 159. Both tau tracers showed similar tau pathology distribution but presented a distinct off-target signal pattern on visual read. SUVR measurements for [18F]PI-2620 and [18F]RO948 were highly correlated in all Braak regions (R2 range [0.65–0.80]). Regarding off-target signal, [18F]PI-2620 had higher SUVRs in vascular structures, and [18F]RO948 had higher SUVRs in the skull/meninges. Conclusions: In a cohort of individuals at early stages of the AD continuum, tau PET tracers [18F]PI-2620 and [18F]RO948 showed similar in-vivo uptake in all Braak regions and distinct off-target signal. These preliminary results support the development of standardized quantification scales for tau deposition that are tracer-independent. Trial registration: AEMPS EudraCT 2021–000473-83. Registered 30 December 2021.
KW - Alzheimer
KW - FACEHBI
KW - Mild cognitive impairment
KW - Positron emission tomography
KW - Subjective cognitive decline
KW - Tau
KW - [18F]PI-2620
KW - [18F]RO948
UR - http://www.scopus.com/inward/record.url?scp=85210581459&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85210581459&partnerID=8YFLogxK
U2 - 10.1186/s13195-024-01622-5
DO - 10.1186/s13195-024-01622-5
M3 - Article
C2 - 39605030
AN - SCOPUS:85210581459
SN - 1758-9193
VL - 16
JO - Alzheimer's Research and Therapy
JF - Alzheimer's Research and Therapy
IS - 1
M1 - 257
ER -